Sign In
Buy NUVL
$90.18
-1.17 (-1.28%)
At Close: Jun 03, 2026
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
06:30am, Wednesday, 27'th May 2026
New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026 Veteran biopha
Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA s
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
06:30am, Thursday, 07'th May 2026
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of Septe
Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal
02:22pm, Thursday, 30'th Apr 2026
Nuvalent is positioned as a high-quality late-stage biotech with two near-commercial precision oncology assets, not a traditional value play. NUVL's robust $1.37B cash position and recent $500M raise
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a
Evergreen Capital Management LLC Purchases New Position in Nuvalent, Inc. $NUVL
04:03am, Saturday, 25'th Apr 2026
Evergreen Capital Management LLC purchased a new stake in shares of Nuvalent, Inc. (NASDAQ: NUVL) during the undefined quarter, according to its most recent disclosure with the SEC. The fund purchased
Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Nuvalen
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
04:01pm, Friday, 17'th Apr 2026
Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
06:30am, Tuesday, 07'th Apr 2026
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
Alexandra Balcom Sells 11,430 Shares of Nuvalent (NASDAQ:NUVL) Stock
04:50am, Sunday, 05'th Apr 2026
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) CFO Alexandra Balcom sold 11,430 shares of Nuvalent stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $105.21,
CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of “Moderate Buy” by Analysts
02:24am, Tuesday, 17'th Mar 2026
Nuvalent, Inc. (NASDAQ: NUVL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the sixteen research firms that are presently covering the company, Marketbeat.com reports.
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
08:00pm, Monday, 16'th Mar 2026
Vestal Point Capital sold 1,054,000 Nuvalent shares in the fourth quarter, an estimated $103.93 million trade based on quarterly average pricing. The fund's quarter-end Nuvalent position value decline
Nuvalent, Inc. $NUVL Shares Sold by ArrowMark Colorado Holdings LLC
04:26am, Sunday, 15'th Mar 2026
ArrowMark Colorado Holdings LLC cut its stake in Nuvalent, Inc. (NASDAQ: NUVL) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
Does Nuvalent (NUVL) Have the Potential to Rally 37.26% as Wall Street Analysts Expect?
10:55am, Friday, 27'th Feb 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in Nuvalent (NUVL). While the effectiveness of this highly sought-after metric is questionable, the posit
